SNIPR001
AXP000216.1 · Phage therapy
- Platform
- CRISPR-armed phage cocktail (four phages)
- Originator
- SNIPR Biome
- Sponsor
- SNIPR Biome
Names
| Name | Type | Source |
|---|---|---|
| SNIPR001 | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Escherichia coli bacteriophage (four-phage cocktail)
- Replication
- replicating
- Modifications
- phages armed with a CRISPR-Cas system directed at E. coli
- Transgenes
- CRISPR-Cas
- Route
- oral
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06938867 | Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant | Recruiting | Phase 1/2 | 2024-12-04 | 2027-10 | 66 | Allogenic Transplant Patients; E Coli Infections |
| NCT05277350 | A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects | Completed | Phase 1 | 2022-03-24 | 2022-11-30 | 36 | Bloodstream Infection; E.Coli Infections |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41785880 | Safety, recovery, and pharmacodynamics of CRISPR-Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study. | The Lancet. Microbe | 2026 | cited by trial NCT05277350 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42262436 | CRISPR-based gene editing for antimicrobial resistance control in human medicine. | Archives of microbiology | 2026 | name in abstract: SNIPR001 |
| PMID 42578807 | First-in-Human Adjunctive Bacteriophage Therapy for Malakoplakia. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2026 | name in abstract: SNIPR001 |
| PMID 43010175 | Engineered bacteriophages as precision antimicrobials against multidrug-resistant ESKAPE pathogens: molecular engineering strategies, clinical translation, and the crystallizing global regulatory landscape. | Future science OA | 2026 | name in abstract: SNIPR001 |
| PMID 40733529 | Armed Phages: A New Weapon in the Battle Against Antimicrobial Resistance. | Viruses | 2025 | name in abstract: SNIPR001 |
| PMID 37142704 | Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice. | Nature biotechnology | 2024 | name in abstract: SNIPR001 |
Notes
Four E. coli phages armed with a CRISPR-Cas payload, given orally to reduce gut E. coli in haematological cancer patients at risk of bloodstream infection. Phase 1 NCT05277350 in healthy volunteers; phase 1b/2a NCT06938867 in patients before allogeneic HSCT.
How to cite
SNIPR001 (AXP000216.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000216.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.